retatrutide phase 2 trial type 2 diabetes Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, conducted in the USA retatrutide phase 2 trial type

Mississippi residents with prediabetes or early metabolic dysfunction can often reverse these conditions through proper hormonal support

(42:49) Addressing the fears surrounding these GLP-1s

Higher mortality in acute coronary syndrome patients without standard modifiable risk factors: results from a global meta-analysis of 1,285,722 patients

A case report found that taking very high doses of over 5 grams of extended-release niacin can lead to metabolic acidosis, a buildup of acid in body fluids, as well as acute liver failure both of which can be fatal ( Keep in mind that these potentially deadly side effects are associated with taking exceptionally high doses of vitamins